The human L1 element: A potential biomarker in cancer prognosis, current status and future directions

Current Molecular Medicine

Volumn 11, Issue 4, 2011, Pages 286-303

  Piskareva, O ^a   Lackington, W ^a   Lemass, D ^a   Hendrick, C ^a   Doolan, P ^a   Barron, N ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Biomarker; Cancer; Detection; Human; L1 element; LINE 1; Retrotransposon

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; B RAF KINASE; BENZENE; BISULFITE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; MOLECULAR MARKER; NUCLEIC ACID; OPEN READING FRAME 2 PROTEIN; PROTEIN P40; PROTEOME; RNA; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG;

ANALYTIC METHOD; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CHIMERA; CHROMOSOMAL INSTABILITY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; COMBINED BISULFITE RESTRICTION ANALYSIS; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; GENE LOCATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HIGH RESOLUTION MELTING ASSAY; HUMAN; HUMAN LONG INTERSPERSED NUCLEAR ELEMENT 1; HYPERMETHYLATION; HYPOMETHYLATION; INHERITANCE; LEUKEMIA REMISSION; LOW DRUG DOSE; METHYLATION SENSITIVE SINGLE NUCLEOTIDE PRIMER EXTENSION; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; OPEN READING FRAME; OPEN READING FRAME 1; OPEN READING FRAME 2; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; PYROSEQUENCING; RESTRICTION MAPPING; RETROPOSON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; RNA TRANSLATION; SOUTHERN BLOTTING; SURVIVAL TIME; TRANSCRIPTOMICS; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 79958163076     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411795677954     Document Type: Review

References (156)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. World Health Organization. Fact Sheets. Cancer 2010.
3. Lander ES, Linton LM, Birren B, et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
4. Ostertag EM, Kazazian HH, Jr. Biology of mammalian L1 retrotransposons. Annu Rev Genet 2001; 35: 501-38.
5. Babushok DV, Kazazian HH, Jr. Progress in understanding the biology of the human mutagen LINE-1. Hum Mutat 2007; 28: 527-39.
6. Iskow RC, McCabe MT, Mills RE, et al. Natural mutagenesis of human genomes by endogenous retrotransposons. Cell 2010; 141: 1253-61.
7. Schulz WA. L1 retrotransposons in human cancers. J Biomed Biotechnol 2006; 2006: 83672.
8. Matlik K, Redik K, Speek M. L1 antisense promoter drives tissue-specific transcription of human genes. J Biomed Biotechnol 2006; 2006: 71753.
9. Speek M. Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol 2001; 21: 1973-85.
10. Shephard EA, Chandan P, Stevanovic-Walker M, Edwards M, Phillips IR. Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse. Biochem J 2007; 406: 491-9.
11. Wolff EM, Byun HM, Han HF, et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 2010; 6: e1000917.
12. Weber B, Kimhi S, Howard G, Eden A, Lyko F. Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene 2010; 29: 5775-84.
13. Belancio VP, Roy-Engel AM, Pochampally RR, Deininger P. Somatic expression of LINE-1 elements in human tissues. Nucleic Acids Res 2010; 38: 3909-22.
14. Sinibaldi-Vallebona P, Lavia P, Garaci E, Spadafora C. A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy. Genes Chromosomes Cancer 2006; 45: 1-10.
15. Sciamanna I, Landriscina M, Pittoggi C, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005; 24: 3923-31.
16. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
17. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007; 1775: 138-62.
18. Ehrlich M, Gama-Sosa MA, Huang LH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982; 10: 2709-21.
19. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
20. Thayer RE, Singer MF, Fanning TG. Undermethylation of specific LINE-1 sequences in human cells producing a LINE-1-encoded protein. Gene 1993; 133: 273-7.
21. Swergold GD. Identification, characterization, and cell specificity of a human LINE-1 promoter. Mol Cell Biol 1990; 10: 6718-29.
22. Woodcock DM, Lawler CB, Linsenmeyer ME, Doherty JP, Warren WD. Asymmetric methylation in the hypermethylated CpG promoter region of the human L1 retrotransposon. J Biol Chem 1997; 272: 7810-6.
23. Hata K, Sakaki Y. Identification of critical CpG sites for repression of L1 transcription by DNA methylation. Gene 1997; 189: 227-34.
24. Steinhoff C, Schulz WA. Transcriptional regulation of the human LINE-1 retrotransposon L1.2B. Mol Genet Genomics 2003; 270: 394-402.
25. Alves G, Tatro A, Fanning T. Differential methylation of human LINE-1 retrotransposons in malignant cells. Gene 1996; 176: 39-44.
26. Phokaew C, Kowudtitham S, Subbalekha K, Shuangshoti S, Mutirangura A. LINE-1 methylation patterns of different loci in normal and cancerous cells. Nucleic Acids Res 2008; 36: 5704-12.
27. Szpakowski S, Sun X, Lage JM, et al. Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene 2009; 448: 151-67.
28. Pobsook T, Subbalekha K, Sannikorn P, Mutirangura A. Improved measurement of LINE-1 sequence methylation for cancer detection. Clin Chim Acta 2010.
29. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-66.
30. Kondo Y, Issa JP. DNA methylation profiling in cancer. Expert Rev Mol Med 2010; 12: e23.
31. Estecio MR, Gharibyan V, Shen L, et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2007; 2: e399.
32. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307-12.
33. Ewing AD, Kazazian HH, Jr. High-throughput sequencing reveals extensive variation in human-specific L1 content in individual human genomes. Genome Res 2010.
34. Beck CR, Collier P, Macfarlane C, et al. LINE-1 retrotransposition activity in human genomes. Cell 2010; 141: 1159-70.
35. Huang CR, Schneider AM, Lu Y, et al. Mobile interspersed repeats are major structural variants in the human genome. Cell 2010; 141: 1171-82.
36. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 2010; 11: 191-203.
37. Cottrell SE. Molecular diagnostic applications of DNA methylation technology. Clin Biochem 2004; 37: 595-604.
38. Sepulveda AR, Jones D, Ogino S, et al. CpG methylation analysis-current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn 2009; 11: 266-78.
39. Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005; 33: 6823-36.
40. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38.
41. Vaissiere T, Cuenin C, Paliwal A, et al. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics 2009; 4: 221-30.
42. Stanzer S, Balic M, Strutz J, et al. Rapid and reliable detection of LINE-1 hypomethylation using high-resolution melting analysis. Clin Biochem 2010; 43: 1443-8.
43. Aparicio A, North B, Barske L, et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 2009; 4: 176-84.
44. Irahara N, Nosho K, Baba Y, et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010; 12: 177-83.
45. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009; 137: 1609,20. e1-3.
46. Ahn JB, Chung WB, Maeda O, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2010.
47. Zhu ZZ, Hou L, Bollati V, et al. Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. Int J Epidemiol 2010.
48. Ibrahim AE, Arends MJ, Silva AL, et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut 2010.
49. Hsiung DT, Marsit CJ, Houseman EA, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 108-14.
50. Chalitchagorn K, Shuangshoti S, Hourpai N, et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004; 23: 8841-6.
51. Daskalos A, Nikolaidis G, Xinarianos G, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2009; 124: 81-7.
52. Richards KL, Zhang B, Baggerly KA, et al. Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One 2009; 4: e4941.
53. Igarashi S, Suzuki H, Niinuma T, et al. A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clin Cancer Res 2010; 16: 5114-23.
54. Pornthanakasem W, Kongruttanachok N, Phuangphairoj C, et al. LINE-1 methylation status of endogenous DNA doublestrand breaks. Nucleic Acids Res 2008; 36: 3667-75.
55. Choi SH, Worswick S, Byun HM, et al. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer 2009; 125: 723-9.
56. Florl AR, Steinhoff C, Muller M, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004; 91: 985-94.
57. Bollati V, Schwartz J, Wright R, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. Mech Ageing Dev 2009; 130: 234-9.
58. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-42.
59. Baba Y, Huttenhower C, Nosho K, et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010; 9: 125.
60. Ogino S, Nosho K, Irahara N, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009; 27: 4591-8.
61. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008; 100: 1734-8.
62. Figueiredo JC, Grau MV, Wallace K, et al. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev 2009; 18: 1041-9.
63. Cho NY, Kim BH, Choi M, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007; 211: 269-77.
64. Cho NY, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch 2009; 454: 17-23.
65. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999; 39: 166-74.
66. Schulz WA, Elo JP, Florl AR, et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 2002; 35: 58-65.
67. Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68: 8954-67.
68. Laner T, Schulz WA, Engers R, Muller M, Florl AR. Hypomethylation of the XIST gene promoter in prostate cancer. Oncol Res 2005; 15: 257-64.
69. Schulz WA, Alexa A, Jung V, et al. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 2007; 6: 14.
70. Firestein R, Shima K, Nosho K, et al. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer 2010; 126: 2863-73.
71. Hazra A, Fuchs CS, Kawasaki T, Kirkner GJ, Hunter DJ, Ogino S. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control 2010; 21: 331-45.
72. Nosho K, Shima K, Irahara N, et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res 2009; 15: 3663-71.
73. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008; 122: 2767-73.
74. Goel A, Xicola RM, Nguyen TP, et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2010; 138: 1854-62.
75. An B, Kondo Y, Okamoto Y, et al. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. Int J Cancer 2010; 127: 2095-105.
76. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis 2004; 19: 95-101.
77. Iacopetta B, Grieu F, Phillips M, et al. Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa. Cancer Sci 2007; 98: 1454-60.
78. Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S, Kim YS. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 2005; 11: 8564-9.
79. Kwon HJ, Kim JH, Bae JM, Cho NY, Kim TY, Kang GH. DNA methylation changes in ex-adenoma carcinoma of the large intestine. Virchows Arch 2010; 457: 433-41.
80. Kawakami K, Matsunoki A, Kaneko M, Saito K, Watanabe G, Minamoto T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci 2010.
81. Choi IS, Estecio MR, Nagano Y, et al. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol 2007; 20: 802-10.
82. Kim MJ, White-Cross JA, Shen L, Issa JP, Rashid A. Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod Pathol 2009; 22: 442-9.
83. Trankenschuh W, Puls F, Christgen M, et al. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PLoS One 2010; 5: e13688.
84. Kim BH, Cho NY, Shin SH, Kwon HJ, Jang JJ, Kang GH. CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma. Virchows Arch 2009; 455: 343-51.
85. Tangkijvanich P, Hourpai N, Rattanatanyong P, Wisedopas N, Mahachai V, Mutirangura A. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta 2007; 379: 127-33.
86. Formeister EJ, Tsuchiya M, Fujii H, Shpyleva S, Pogribny IP, Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and nontumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res 2010; 692: 26-33.
87. Matsubayashi H, Skinner HG, Iacobuzio-Donahue C, et al. Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes. Clin Gastroenterol Hepatol 2005; 3: 752-60.
88. Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001; 61: 4238-43.
89. Takai D, Yagi Y, Habib N, Sugimura T, Ushijima T. Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn J Clin Oncol 2000; 30: 306-9.
90. Dammann RH, Kirsch S, Schagdarsurengin U, et al. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. Int J Oncol 2010; 36: 171-9.
91. Menendez L, Benigno BB, McDonald JF. L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer 2004; 3: 12.
92. Fang F, Balch C, Schilder J, et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010; 116: 4043-53.
93. Pattamadilok J, Huapai N, Rattanatanyong P, et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18: 711-7.
94. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoterspecific and global DNA methylation status in ovarian cancer. Clin Cancer Res 2008; 14: 3283-90.
95. Furniss CS, Marsit CJ, Houseman EA, Eddy K, Kelsey KT. Line region hypomethylation is associated with lifestyle and differs by human papillomavirus status in head and neck squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 966-71.
96. Smith IM, Mydlarz WK, Mithani SK, Califano JA. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer 2007; 121: 1724-8.
97. Daskalos A, Logotheti S, Markopoulou S, et al. Global DNA hypomethylation-induced DeltaNp73 transcriptional activation in non-small cell lung cancer. Cancer Lett 2011; 300: 79-86.
98. Jin M, Kawakami K, Fukui Y, et al. Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels. Cancer Sci 2009; 100: 2325-30.
99. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res 2010; 16: 2418-26.
100. Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer 1999; 80: 1312-21.
101. Neuhausen A, Florl AR, Grimm MO, Schulz WA. DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 2006; 5: 993-1001.
102. Wilhelm CS, Kelsey KT, Butler R, et al. Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res 2010; 16: 1682-9.
103. Geisel J, Schorr H, Heine GH, et al. Decreased p66Shc promoter methylation in patients with end-stage renal disease. Clin Chem Lab Med 2007; 45: 1764-70.
104. Yamamoto E, Toyota M, Suzuki H, et al. LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev 2008; 17: 2555-64.
105. Hou L, Wang H, Sartori S, et al. Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int J Cancer 2010; 127: 1866-74.
106. Yoo EJ, Park SY, Cho NY, Kim N, Lee HS, Kang GH. Helicobacter pylori-infection-associated CpG island hypermethylation in the stomach and its possible association with polycomb repressive marks. Virchows Arch 2008; 452: 515-24.
107. Wang GS, Wang MW, Wu BY, Yang XY, Wang WH, You WD. LINE-1 family member GCRG123 gene is up-regulated in human gastric signet-ring cell carcinoma. World J Gastroenterol 2008; 14: 758-63.
108. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. Leuk Res 2008; 32: 487-90.
109. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 2005; 24: 7213-23.
110. Bollati V, Fabris S, Pegoraro V, et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 2009; 30: 1330-5.
111. Fabris S, Bollati V, Agnelli L, et al. Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics 2011; 6.
112. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of lowdose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948-56.
113. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899-906.
114. Kitkumthorn N, Mutirangura A. LINE-1 methylation difference between ameloblastoma and keratocystic odontogenic tumor. Oral Dis 2010; 16: 286-91.
115. Subbalekha K, Pimkhaokham A, Pavasant P, et al. Detection of LINE-1s hypomethylation in oral rinses of oral squamous cell carcinoma patients. Oral Oncol 2009; 45: 184-91.
116. Lee JJ, Geli J, Larsson C, et al. Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer. Int J Oncol 2008; 33: 861-9.
117. Geli J, Kiss N, Karimi M, et al. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior. Clin Cancer Res 2008; 14: 2551-9.
118. Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci 2008; 1137: 171-4.
119. Mirabello L, Savage SA, Korde L, Gadalla SM, Greene MH. LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Med Genet 2010; 11: 77.
120. Shuangshoti S, Hourpai N, Pumsuk U, Mutirangura A. Line-1 hypomethylation in multistage carcinogenesis of the uterine cervix. Asian Pac J Cancer Prev 2007; 8: 307-9.
121. Kile ML, Baccarelli A, Tarantini L, Hoffman E, Wright RO, Christiani DC. Correlation of global and gene-specific DNA methylation in maternal-infant pairs. PLoS One 2010; 5: e13730.
122. El-Maarri O, Becker T, Junen J, et al. Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum Genet 2007; 122: 505-14.
123. Bollati V, Baccarelli A, Hou L, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res 2007; 67: 876-80.
124. Rakyan VK, Beck S. Epigenetic variation and inheritance in mammals. Curr Opin Genet Dev 2006; 16: 573-7.
125. Symer DE, Connelly C, Szak ST, et al. Human l1 retrotransposition is associated with genetic instability in vivo. Cell 2002; 110: 327-38.
126. Gilbert N, Lutz-Prigge S, Moran JV. Genomic deletions created upon LINE-1 retrotransposition. Cell 2002; 110: 315-25.
127. Kazazian HH, Jr, Goodier JL. LINE drive. retrotransposition and genome instability. Cell 2002; 110: 277-80.
128. Dotzlaw H, Alkhalaf M, Murphy LC. Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol 1992; 6: 773-85.
129. Murphy LC, Dotzlaw H, Hamerton J, Schwarz J. Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples. Breast Cancer Res Treat 1993; 26: 149-61.
130. Kuo KW, Sheu HM, Huang YS, Leung WC. Expression of transposon LINE-1 is relatively human-specific and function of the transcripts may be proliferation-essential. Biochem Biophys Res Commun 1998; 253: 566-70.
131. Skowronski J, Singer MF. Expression of a cytoplasmic LINE-1 transcript is regulated in a human teratocarcinoma cell line. Proc Natl Acad Sci U S A 1985; 82: 6050-4.
132. Skowronski J, Fanning TG, Singer MF. Unit-length line-1 transcripts in human teratocarcinoma cells. Mol Cell Biol 1988; 8: 1385-97.
133. Cruickshanks HA, Tufarelli C. Isolation of cancer-specific chimeric transcripts induced by hypomethylation of the LINE-1 antisense promoter. Genomics 2009; 94: 397-406.
134. Bratthauer GL, Fanning TG. Active LINE-1 retrotransposons in human testicular cancer. Oncogene 1992; 7: 507-10.
135. Leibold DM, Swergold GD, Singer MF, Thayer RE, Dombroski BA, Fanning TG. Translation of LINE-1 DNA elements in vitro and in human cells. Proc Natl Acad Sci U S A 1990; 87: 6990-4.
136. Bratthauer GL, Fanning TG. LINE-1 retrotransposon expression in pediatric germ cell tumors. Cancer 1993; 71: 2383-6.
137. Asch HL, Eliacin E, Fanning TG, Connolly JL, Bratthauer G, Asch BB. Comparative expression of the LINE-1 p40 protein in human breast carcinomas and normal breast tissues. Oncol Res 1996; 8: 239-47.
138. Bratthauer GL, Cardiff RD, Fanning TG. Expression of LINE-1 retrotransposons in human breast cancer. Cancer 1994; 73: 2333-6.
139. Nangia-Makker P, Sarvis R, Visscher DW, Bailey-Penrod J, Raz A, Sarkar FH. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res Treat 1998; 49: 171-83.
140. Hohjoh H, Singer MF. Cytoplasmic ribonucleoprotein complexes containing human LINE-1 protein and RNA. EMBO J 1996; 15: 630-9.
141. Ergun S, Buschmann C, Heukeshoven J, et al. Cell typespecific expression of LINE-1 open reading frames 1 and 2 in fetal and adult human tissues. J Biol Chem 2004; 279: 27753-63.
142. Su Y, Davies S, Davis M, et al. Expression of LINE-1 p40 protein in pediatric malignant germ cell tumors and its association with clinicopathological parameters: A report from the Children's Oncology Group. Cancer Lett 2007; 247: 204-12.
143. Rangwala SH, Zhang L, Kazazian HH, Jr. Many LINE1 elements contribute to the transcriptome of human somatic cells. Genome Biol 2009; 10: R100.
144. Harris CR, Normart R, Yang Q, et al. Association of Nuclear Localization of a Long Interspersed Nuclear Element-1 Protein in Breast Tumors with Poor Prognostic Outcomes. Genes Cancer 2010; 1: 115-24.
145. Piskareva O, Schmatchenko V. Immunodetection of ORF1 protein encoded by the L1 retrotransposon in human cell lines. Anticancer Research 2003; 24: 530.
146. Deragon JM, Sinnett D, Labuda D. Reverse transcriptase activity from human embryonal carcinoma cells NTera2D1. EMBO J 1990; 9: 3363-8.
147. Mangiacasale R, Pittoggi C, Sciamanna I, et al. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene 2003; 22: 2750-61.
148. Banaz-Yasar F, Steffen G, Hauschild J, Bongartz BM, Schumann GG, Ergun S. LINE-1 retrotransposition events affect endothelial proliferation and migration. Histochem Cell Biol 2010; 134: 581-9.
149. Piskareva O, Denmukhametova S, Schmatchenko V. Functional reverse transcriptase encoded by the human LINE-1 from baculovirus-infected insect cells. Protein Expr Purif 2003; 28: 125-30.
150. Montoya-Durango DE, Liu Y, Teneng I, et al. Epigenetic control of mammalian LINE-1 retrotransposon by retinoblastoma proteins. Mutat Res 2009; 665: 20-8.
151. Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003; 49: 1-6.
152. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100: 1432-8.
153. Ohnami S, Sato Y, Yoshimura K, et al. His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk. Gastroenterology 2008; 135: 477-88.
154. Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 2010; 10: 6.
155. Gasche JA, Hoffmann J, Boland CR, Goel A. Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer 2010.
156. Tellez CS, Shen L, Estecio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res 2009; 19: 146-55.